Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 566

1.

10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals.

Tourdot S, Abdolzade-Bavil A, Bessa J, Broët P, Fogdell-Hahn A, Giorgi M, Jawa V, Kuranda K, Legrand N, Pattijn S, Pedras-Vasconcelos JA, Rudy A, Salmikangas P, Scott DW, Snoeck V, Smith N, Spindeldreher S, Kramer D.

MAbs. 2020 Jan-Dec;12(1):1725369. doi: 10.1080/19420862.2020.1725369.

PMID:
32063088
2.

Ultrasensitive detection of NOTCH1 delCT mutations in chronic lymphocytic leukemia by ddPCR reveals high frequency of subclonal mutations and predicts clinical outcome in cases with trisomy 12.

Hoofd C, Huang SJ, Gusscott S, Lam S, Wong R, Johnston A, Ben-Neriah S, Steidl C, Scott DW, Bruyere H, Gillan TL, Toze CL, Gerrie AS, Weng AP.

J Mol Diagn. 2020 Feb 6. pii: S1525-1578(20)30015-5. doi: 10.1016/j.jmoldx.2020.01.008. [Epub ahead of print]

PMID:
32036086
3.

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.

Scott DW, Pratt KP.

Front Immunol. 2020 Jan 17;10:3078. doi: 10.3389/fimmu.2019.03078. eCollection 2019. Review.

4.

Tolerating Factor VIII: Recent Progress.

Lacroix-Desmazes S, Voorberg J, Lillicrap D, Scott DW, Pratt KP.

Front Immunol. 2020 Jan 10;10:2991. doi: 10.3389/fimmu.2019.02991. eCollection 2019. Review.

5.

Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11.

Croci GA, Hoster E, Beà S, Clot G, Enjuanes A, Scott DW, Cabeçadas J, Veloza L, Campo E, Clasen-Linde E, Goswami RS, Helgeland L, Pileri S, Rymkiewicz G, Reinke S, Dreyling M, Klapper W.

Virchows Arch. 2020 Jan 23. doi: 10.1007/s00428-020-02750-7. [Epub ahead of print]

PMID:
31975037
6.

Objective quantification of BCL2 protein by multiplex immunofluorescence in routine biopsy samples of diffuse large B-cell lymphoma demonstrates associations with survival and BCL2 gene alterations.

Chen L, Tyryshkin K, Moore A, Scott DW, Steidl C, Li Y, Shepherd LE, Rauh M, Deng L, Good D, Virk S, Chen BE, Crocker S, Baetz T, LeBrun DP.

Leuk Lymphoma. 2020 Jan 16:1-11. doi: 10.1080/10428194.2020.1713318. [Epub ahead of print]

PMID:
31942813
7.

Genetic Engineering of T Cells for Immune Tolerance.

Scott DW.

Mol Ther Methods Clin Dev. 2019 Dec 24;16:103-107. doi: 10.1016/j.omtm.2019.11.022. eCollection 2020 Mar 13. Review.

8.

Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma.

Aoki T, Chong LC, Takata K, Milne K, Hav M, Colombo A, Chavez EA, Nissen M, Wang X, Miyata-Takata T, Lam V, Viganò E, Woolcock BW, Telenius A, Li MY, Healy S, Ghesquiere C, Kos D, Goodyear T, Veldman J, Zhang AW, Kim J, Saberi S, Ding J, Farinha P, Weng AP, Savage KJ, Scott DW, Krystal G, Nelson BH, Mottok A, Merchant A, Shah SP, Steidl C.

Cancer Discov. 2019 Dec 19. doi: 10.1158/2159-8290.CD-19-0680. [Epub ahead of print]

PMID:
31857391
9.

Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphoma.

Hayden AR, Lee DG, Villa D, Gerrie AS, Scott DW, Slack GW, Sehn LH, Connors JM, Savage KJ.

Br J Haematol. 2019 Dec 10. doi: 10.1111/bjh.16293. [Epub ahead of print]

PMID:
31822034
10.

Fast dissolving glucose porogens for early calcium phosphate cement degradation and bone regeneration.

Grosfeld EC, Smith BT, Santoro M, Lodoso-Torrecilla I, Jansen JA, Ulrich DJ, Melchiorri AJ, Scott DW, Mikos AG, van den Beucken JJJP.

Biomed Mater. 2020 Feb 17;15(2):025002. doi: 10.1088/1748-605X/ab5f9c.

PMID:
31810074
11.

Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray.

Villa D, Tan KL, Steidl C, Ben-Neriah S, Al Moosawi M, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Scott DW, Gascoyne RD, Slack GW.

Blood Adv. 2019 Dec 10;3(23):3953-3961. doi: 10.1182/bloodadvances.2019000989.

12.

Multimaterial Dual Gradient Three-Dimensional Printing for Osteogenic Differentiation and Spatial Segregation.

Smith BT, Bittner SM, Watson E, Smoak MM, Diaz-Gomez L, Molina ER, Kim YS, Hudgins CD, Melchiorri AJ, Scott DW, Grande-Allen KJ, Yoo JJ, Atala A, Fisher JP, Mikos AG.

Tissue Eng Part A. 2019 Dec 27. doi: 10.1089/ten.TEA.2019.0204. [Epub ahead of print]

PMID:
31696784
13.

Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity.

Nissen MD, Kusakabe M, Wang X, Simkin G, Gracias D, Tyshchenko K, Hill A, Meskas J, Hung S, Chavez EA, Ennishi D, Aoki T, Sarkozy C, Connors JM, Farinha P, Slack GW, Gascoyne RD, Brinkman RR, Scott DW, Steidl C, Weng AP.

Cytometry A. 2019 Oct 22. doi: 10.1002/cyto.a.23919. [Epub ahead of print]

PMID:
31637838
14.

Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma.

Molina ER, Chim LK, Salazar MC, Mehta SM, Menegaz BA, Lamhamedi-Cherradi SE, Satish T, Mohiuddin S, McCall D, Zaske AM, Cuglievan B, Lazar AJ, Scott DW, Grande-Allen JK, Ludwig JA, Mikos AG.

Acta Biomater. 2019 Dec;100:38-51. doi: 10.1016/j.actbio.2019.09.029. Epub 2019 Sep 19.

PMID:
31542501
15.

The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.

Hilton LK, Tang J, Ben-Neriah S, Alcaide M, Jiang A, Grande BM, Rushton CK, Boyle M, Meissner B, Scott DW, Morin RD.

Blood. 2019 Oct 31;134(18):1528-1532. doi: 10.1182/blood.2019002600.

16.

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.

Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D.

J Clin Oncol. 2019 Dec 10;37(35):3359-3368. doi: 10.1200/JCO.19.00743. Epub 2019 Sep 9.

PMID:
31498031
17.

Engineered ovalbumin-expressing regulatory T cells protect against anaphylaxis in ovalbumin-sensitized mice.

Abdeladhim M, Zhang AH, Kropp LE, Lindrose AR, Venkatesha SH, Mitre E, Scott DW.

Clin Immunol. 2019 Oct;207:49-54. doi: 10.1016/j.clim.2019.07.009. Epub 2019 Jul 17.

PMID:
31325629
18.

Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.

Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, Gerrie AS, Ferguson D, Cafferty F, Slack GW, Farinha P, Skinnider B, Connors JM, Sehn LH.

Blood. 2019 Aug 29;134(9):761-764. doi: 10.1182/blood.2019000258. Epub 2019 Jul 12.

PMID:
31300404
19.

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.

Mottok A, Hung SS, Chavez EA, Woolcock B, Telenius A, Chong LC, Meissner B, Nakamura H, Rushton C, Viganò E, Sarkozy C, Gascoyne RD, Connors JM, Ben-Neriah S, Mungall A, Marra MA, Siebert R, Scott DW, Savage KJ, Steidl C.

Blood. 2019 Sep 5;134(10):802-813. doi: 10.1182/blood.2019001126. Epub 2019 Jul 10.

PMID:
31292115
20.

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.

Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P, Gould C, Birch S, Sehn LH, Sovani V, Ward MS, Augustson B, Biccler J, Connors JM, Scott DW, Gandhi MK, Savage KJ, El-Galaly T, Villa D, Cheah CY.

Blood Adv. 2019 Jul 9;3(13):2013-2021. doi: 10.1182/bloodadvances.2019000251.

21.

Balancing immunity and tolerance in gene therapy for inherited and acquired diseases.

Scott DW, Mingozzi F.

Cell Immunol. 2019 Aug;342:103945. doi: 10.1016/j.cellimm.2019.103945. Epub 2019 Jun 14. No abstract available.

PMID:
31229195
22.

Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma.

Nowakowski GS, Chiappella A, Witzig TE, Scott DW, Spina M, Gascoyne RD, Zhang L, Russo J, Kang J, Zhang J, Xu Y, Vitolo U.

Haematologica. 2020 Jan 31;105(2):e72-e75. doi: 10.3324/haematol.2019.220475. Print 2020. No abstract available.

23.

Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.

Costa S, Scott DW, Steidl C, Peacock SJ, Regier DA.

Curr Oncol. 2019 Apr;26(2):108-113. doi: 10.3747/co.26.4565. Epub 2019 Apr 1.

24.

Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma.

Biccler JL, Savage KJ, Brown PDN, Jørgensen J, Larsen TS, Poulsen CB, Stoltenberg D, Sehn LH, Scott DW, Gerrie AS, Jakobsen LH, Bøgsted M, El-Galaly TC, Villa D.

Leuk Lymphoma. 2019 Oct;60(10):2516-2523. doi: 10.1080/10428194.2019.1594219. Epub 2019 Apr 3.

PMID:
30943052
25.

Fabrication and mechanical characterization of 3D printed vertical uniform and gradient scaffolds for bone and osteochondral tissue engineering.

Bittner SM, Smith BT, Diaz-Gomez L, Hudgins CD, Melchiorri AJ, Scott DW, Fisher JP, Mikos AG.

Acta Biomater. 2019 May;90:37-48. doi: 10.1016/j.actbio.2019.03.041. Epub 2019 Mar 21.

PMID:
30905862
26.

Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.

Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D, Sehn LH, Connors JM, Gascoyne RD, Feldman AL, Farinha P, Steidl C, Scott DW, Slack GW, Savage KJ.

Br J Haematol. 2019 Aug;186(3):e28-e31. doi: 10.1111/bjh.15860. Epub 2019 Mar 14. No abstract available.

PMID:
30873584
27.

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW.

Blood. 2019 Apr 18;133(16):1762-1765. doi: 10.1182/blood-2018-08-870915. Epub 2019 Feb 5.

PMID:
30723079
28.

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.

Ennishi D, Takata K, Béguelin W, Duns G, Mottok A, Farinha P, Bashashati A, Saberi S, Boyle M, Meissner B, Ben-Neriah S, Woolcock BW, Telenius A, Lai D, Teater M, Kridel R, Savage KJ, Sehn LH, Morin RD, Marra MA, Shah SP, Connors JM, Gascoyne RD, Scott DW, Melnick AM, Steidl C.

Cancer Discov. 2019 Apr;9(4):546-563. doi: 10.1158/2159-8290.CD-18-1090. Epub 2019 Jan 31.

PMID:
30705065
29.

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, Farinha P, Takata K, Miyata-Takata T, Craig J, Mottok A, Meissner B, Saberi S, Bashashati A, Villa D, Savage KJ, Sehn LH, Kridel R, Mungall AJ, Marra MA, Shah SP, Steidl C, Connors JM, Gascoyne RD, Morin RD, Scott DW.

J Clin Oncol. 2019 Jan 20;37(3):190-201. doi: 10.1200/JCO.18.01583. Epub 2018 Dec 3.

30.

High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Chong LC, Ben-Neriah S, Slack GW, Freeman C, Ennishi D, Mottok A, Collinge B, Abrisqueta P, Farinha P, Boyle M, Meissner B, Kridel R, Gerrie AS, Villa D, Savage KJ, Sehn LH, Siebert R, Morin RD, Gascoyne RD, Marra MA, Connors JM, Mungall AJ, Steidl C, Scott DW.

Blood Adv. 2018 Oct 23;2(20):2755-2765. doi: 10.1182/bloodadvances.2018023572.

31.

Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.

Arthur SE, Jiang A, Grande BM, Alcaide M, Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L, Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B, Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB, Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD.

Nat Commun. 2018 Oct 1;9(1):4001. doi: 10.1038/s41467-018-06354-3.

32.

Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.

Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM.

Blood. 2018 Nov 29;132(22):2401-2405. doi: 10.1182/blood-2018-05-851154. Epub 2018 Sep 26.

33.

Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo.

Parvathaneni K, Scott DW.

Blood Adv. 2018 Sep 25;2(18):2332-2340. doi: 10.1182/bloodadvances.2018018556.

34.

Dissecting aggressive B-cell lymphoma through genomic analysis - What is clinically relevant?

Scott DW, Rimsza LM.

Best Pract Res Clin Haematol. 2018 Sep;31(3):187-198. doi: 10.1016/j.beha.2018.07.003. Epub 2018 Jul 7. Review.

PMID:
30213388
35.

High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.

Tsang ES, Villa D, Loscocco F, Visani G, Power M, Guiducci B, Clissa C, Song K, Toze C, Abou Mourad Y, Sutherland H, Sanford D, Nantel SH, Sehn LH, Scott DW, Savage KJ, Connors JM, Gerrie AS, Isidori A.

Bone Marrow Transplant. 2019 Mar;54(3):481-484. doi: 10.1038/s41409-018-0328-9. Epub 2018 Aug 31. No abstract available.

PMID:
30171222
36.

SAMHD1 Posttranscriptionally Controls the Expression of Foxp3 and Helios in Human T Regulatory Cells.

Kim YC, Kim KK, Yoon J, Scott DW, Shevach EM.

J Immunol. 2018 Sep 15;201(6):1671-1680. doi: 10.4049/jimmunol.1800613. Epub 2018 Aug 13.

37.

Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.

Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W, Unterhalt M, Kluin-Nelemans HC, Hermine O, Hartmann S, Thorns C, Rymkiewicz G, Holte H, Dreyling M, Hoster E, Rosenwald A.

Br J Haematol. 2019 Feb;184(4):616-624. doi: 10.1111/bjh.15519. Epub 2018 Aug 10.

38.

The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.

Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A.

Br J Haematol. 2018 Oct;183(2):225-234. doi: 10.1111/bjh.15518. Epub 2018 Aug 6.

39.

Incorporation of fast dissolving glucose porogens and poly(lactic-co-glycolic acid) microparticles within calcium phosphate cements for bone tissue regeneration.

Smith BT, Lu A, Watson E, Santoro M, Melchiorri AJ, Grosfeld EC, van den Beucken JJJP, Jansen JA, Scott DW, Fisher JP, Mikos AG.

Acta Biomater. 2018 Sep 15;78:341-350. doi: 10.1016/j.actbio.2018.07.054. Epub 2018 Aug 1.

40.

Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells.

Zhang AH, Yoon J, Kim YC, Scott DW.

J Immunol. 2018 Sep 1;201(5):1434-1441. doi: 10.4049/jimmunol.1701800. Epub 2018 Jul 18.

41.

Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD.

Villa D, Sehn LH, Aquino-Parsons C, Tonseth P, Scott DW, Gerrie AS, Wilson D, Bénard F, Gascoyne RD, Slack GW, Farinha P, Morris J, Pickles T, Connors JM, Savage KJ.

Haematologica. 2018 Dec;103(12):e590-e593. doi: 10.3324/haematol.2018.196782. Epub 2018 Jul 12. No abstract available.

42.

SPX-101 is stable in and retains function after exposure to cystic fibrosis sputum.

Sesma JI, Wu B, Stuhlmiller TJ, Scott DW.

J Cyst Fibros. 2019 Mar;18(2):244-250. doi: 10.1016/j.jcf.2018.06.002. Epub 2018 Jun 20.

43.

Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells.

Kim YC, Zhang AH, Yoon J, Culp WE, Lees JR, Wucherpfennig KW, Scott DW.

J Autoimmun. 2018 Aug;92:77-86. doi: 10.1016/j.jaut.2018.05.003. Epub 2018 May 30.

44.

A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.

Clot G, Jares P, Giné E, Navarro A, Royo C, Pinyol M, Martín-Garcia D, Demajo S, Espinet B, Salar A, Ferrer A, Muntañola A, Aymerich M, Rauert-Wunderlich H, Jaffe ES, Connors JM, Gascoyne RD, Delabie J, López-Guillermo A, Ott G, Wright GW, Staudt LM, Rosenwald A, Scott DW, Rimsza LM, Beà S, Campo E.

Blood. 2018 Jul 26;132(4):413-422. doi: 10.1182/blood-2018-03-838136. Epub 2018 May 16.

45.

Vinculin Force-Sensitive Dynamics at Focal Adhesions Enable Effective Directed Cell Migration.

Rothenberg KE, Scott DW, Christoforou N, Hoffman BD.

Biophys J. 2018 Apr 10;114(7):1680-1694. doi: 10.1016/j.bpj.2018.02.019.

46.

Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs.

Sicard A, Levings MK, Scott DW.

Am J Transplant. 2018 Jun;18(6):1305-1311. doi: 10.1111/ajt.14747. Epub 2018 Apr 21. Review.

47.

Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era.

King RL, Nowakowski GS, Witzig TE, Scott DW, Little RF, Hong F, Gascoyne RD, Kahl BS, Macon WR.

Blood Cancer J. 2018 Feb 28;8(3):27. doi: 10.1038/s41408-018-0064-9.

48.

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.

Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A.

Blood. 2018 May 3;131(18):2060-2064. doi: 10.1182/blood-2017-12-820605. Epub 2018 Feb 23.

49.

FOXP3 renders activated human regulatory T cells resistant to restimulation-induced cell death by suppressing SAP expression.

Katz G, Voss K, Yan TF, Kim YC, Kortum RL, Scott DW, Snow AL.

Cell Immunol. 2018 May;327:54-61. doi: 10.1016/j.cellimm.2018.02.007. Epub 2018 Feb 12.

50.

Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management.

Hung SS, Meissner B, Chavez EA, Ben-Neriah S, Ennishi D, Jones MR, Shulha HP, Chan FC, Boyle M, Kridel R, Gascoyne RD, Mungall AJ, Marra MA, Scott DW, Connors JM, Steidl C.

J Mol Diagn. 2018 Mar;20(2):203-214. doi: 10.1016/j.jmoldx.2017.11.010. Epub 2018 Feb 8.

Supplemental Content

Loading ...
Support Center